-
Operating profit from ongoing operations for PE Films of $12.4
million was $1.4 million lower than the fourth quarter of last year
-
Operating profit from ongoing operations for Flexible Packaging
significantly improved
-
Operating profit from ongoing operations for Bonnell Aluminum of
$9.6 million was exceptionally strong, improving by $2.5 million over
the fourth quarter of 2014
Tredegar Corporation (NYSE:TG, also the “Company” or “Tredegar”) today
reported fourth-quarter financial results for the period ended
December 31, 2015.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in millions, except per share data)
|
|
|
Three Months Ended
December 31,
|
|
|
Year Ended
December 31,
|
|
|
|
2015
|
|
|
2014
|
|
|
2015
|
|
|
2014
|
Net income (loss) from continuing operations as reported under
generally accepted accounting principles (“U.S. GAAP”)
|
|
|
$
|
(5.9
|
)
|
|
|
$
|
13.1
|
|
|
|
$
|
(32.1
|
)
|
|
|
$
|
36.0
|
|
After-tax effects of:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Gains) losses associated with plant shutdowns, asset impairments
and restructurings
|
|
|
|
1.4
|
|
|
|
|
0.3
|
|
|
|
|
3.0
|
|
|
|
|
2.0
|
|
(Gains) losses from sale of assets and other
|
|
|
|
15.5
|
|
|
|
|
(6.0
|
)
|
|
|
|
17.7
|
|
|
|
|
(1.2
|
)
|
Goodwill impairment charge
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
44.5
|
|
|
|
|
—
|
|
Net income from ongoing operations *
|
|
|
$
|
11.0
|
|
|
|
$
|
7.4
|
|
|
|
$
|
33.1
|
|
|
|
$
|
36.8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per share from continuing operations as reported
under U.S. GAAP (diluted)
|
|
|
$
|
(0.18
|
)
|
|
|
$
|
0.40
|
|
|
|
$
|
(0.99
|
)
|
|
|
$
|
1.11
|
|
After-tax effects per diluted share of:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Gains) losses associated with plant shutdowns, asset impairments
and restructurings
|
|
|
|
0.04
|
|
|
|
|
0.01
|
|
|
|
|
0.09
|
|
|
|
|
0.06
|
|
(Gains) losses from sale of assets and other
|
|
|
|
0.48
|
|
|
|
|
(0.18
|
)
|
|
|
|
0.54
|
|
|
|
|
(0.04
|
)
|
Goodwill impairment charge
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
1.37
|
|
|
|
|
—
|
|
Earnings per share from ongoing operations (diluted) *
|
|
|
$
|
0.34
|
|
|
|
$
|
0.23
|
|
|
|
$
|
1.01
|
|
|
|
$
|
1.13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*
|
|
Tredegar’s presentation of net income and earnings per share from
ongoing operations are non-GAAP financial measures that exclude the
after-tax effects of gains or losses associated with plant
shutdowns, asset impairments and restructurings, gains or losses
from the sale of assets and other items, goodwill impairment charges
and operating results and gains or losses on sale for businesses
divested that are included in discontinued operations, which have
been presented separately and removed from net income (loss) and
diluted earnings (loss) per share as reported under U.S. GAAP. Net
income and earnings per share from ongoing operations are used by
management to gauge the operating performance of Tredegar’s ongoing
operations. They are not intended to represent the stand-alone
results for Tredegar’s ongoing operations under U.S. GAAP and should
not be considered as an alternative to net income (loss) or earnings
(loss) per share from continuing operations as defined by U.S. GAAP.
They exclude items that we believe do not relate to Tredegar’s
ongoing operations. Further details regarding the special items that
reconcile net income from ongoing operations to net income from
continuing operations are provided in the Notes to the Financial
Tables in this press release.
|
|
|
|
John D. Gottwald, Tredegar’s president and chief executive officer,
said: “Overall, Tredegar had a solid quarter. Bonnell and Terphane
posted improved operating results with strong volume growth for the
quarter and full year. Our PE Films segment continues to show volume and
profit declines as we manage through lost business and product
transitions in personal care materials. On the positive side, surface
protection films performed well for the quarter and year. We’ve added
R&D resources to PE Films to improve our chances of realizing several
opportunities that we see from new products.”
“Looking forward, we will continue to be challenged over the next couple
of years by product transitions in personal care materials. Meeting
customer needs will be paramount to success, and our prospects improve
considerably if we’re successful in our new product development
initiatives.”
Mr. Gottwald continued, “In light of recently improved operating
efficiencies, our challenge to profit growth at Terphane will continue
to be the poor economic conditions in Brazil and tough competitive
pressures, given the overcapacity in place.”
OPERATIONS REVIEW
PE Films
PE Films is comprised of the Company’s polyolefin-based operations that
manufacture and sell personal care materials, surface protection films,
polyethylene overwrap films and related films for other markets. A
summary of fourth-quarter and full year operating results from ongoing
operations for PE Films is provided below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Favorable/
|
|
|
Year Ended
|
|
|
Favorable/
|
|
|
|
December 31,
|
|
|
(Unfavorable)
|
|
|
December 31,
|
|
|
(Unfavorable)
|
(In Thousands, Except Percentages)
|
|
|
2015
|
|
|
2014
|
|
|
% Change
|
|
|
2015
|
|
|
2014
|
|
|
% Change
|
Sales volume (lbs)
|
|
|
|
38,417
|
|
|
|
41,332
|
|
|
(7.1
|
)%
|
|
|
|
160,283
|
|
|
|
175,203
|
|
|
(8.5
|
)%
|
Net sales
|
|
|
$
|
93,291
|
|
|
$
|
109,448
|
|
|
(14.8
|
)%
|
|
|
$
|
385,550
|
|
|
$
|
464,339
|
|
|
(17.0
|
)%
|
Operating profit from ongoing operations
|
|
|
$
|
12,426
|
|
|
$
|
13,797
|
|
|
(9.9
|
)%
|
|
|
$
|
48,275
|
|
|
$
|
60,971
|
|
|
(20.8
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth-Quarter Results vs. Prior Year Fourth
Quarter
Net sales (sales less freight) in the fourth quarter of 2015 decreased
by $16.2 million versus 2014 primarily due to the following:
-
The loss of business with PE Films’ largest customer related to
various product transitions in personal care materials ($5.5 million);
-
A decline in volume from other customers of personal care materials
and polyethylene overwrap films ($3.6 million);
-
A decrease in average selling prices due to competitive pricing
pressures and lower raw material costs ($1.4 million); and
-
The unfavorable impact from the change in the U.S. dollar value of
currencies for operations outside of the U.S. ($5.7 million).
As noted above, current year sales volume has declined as a result of
the wind down of shipments for certain personal care materials due to
various product transitions and lost business, primarily with PE Films’
largest customer. In addition, efforts to consolidate domestic
manufacturing facilities in PE Films commenced in the third quarter of
2015. This restructuring project is not expected to be completed until
the middle of 2017, and once complete, annual pre-tax cash cost savings
are expected to be approximately $5-6 million. The table below
summarizes the pro forma operating profit from ongoing operations for
the fourth quarters of 2015 and 2014, had the impact of the events noted
above been fully realized in each period:
|
|
|
|
|
|
|
|
|
|
Three Months Ended December 31,
|
(In Thousands)
|
|
|
2015
|
|
|
2014
|
Operating profit from ongoing operations, as reported
|
|
|
$
|
12,426
|
|
|
$
|
13,797
|
Contribution to operating profit from ongoing operations associated
with product transitions & other lost business before restructurings
& fixed costs reduction
|
|
|
|
2,712
|
|
|
|
4,940
|
Operating profit from ongoing operations net of the impact of
business that will be fully eliminated in future periods
|
|
|
|
9,714
|
|
|
|
8,857
|
Estimated future benefit of North American facility consolidation
|
|
|
|
1,300
|
|
|
|
1,300
|
Pro forma estimated operating profit from ongoing operations
|
|
|
$
|
11,014
|
|
|
$
|
10,157
|
|
|
|
|
|
|
|
|
|
Net sales associated with lost business and product transitions that
have yet to be fully eliminated were approximately $6.5 million and
$15.4 million in the fourth quarters of 2015 and 2014, respectively.
Net of the impact of product transitions and lost business, pro forma
estimated operating profit from ongoing operations in the fourth quarter
of 2015 increased by $0.9 million versus the fourth quarter of 2014 due
to the following:
-
Lower volumes and pricing for ongoing personal care films business
($2.4 million);
-
The favorable lag in the pass-through of average resin costs of $2.0
million in the fourth quarter of 2015 versus $0.4 million in 2014;
-
An increase in volume and a favorable mix for surface protection films
partially offset by lower pricing ($1.0 million);
-
An increase in research and development costs incurred to support new
product development ($0.7 million); and
-
A decrease in depreciation expense ($1.4 million) offset by an
increase in foreign currency translation and transaction losses ($0.5
million) and other operating expenses ($0.4 million).
The competitive dynamics in PE Films require continuous development of
new products to improve cost and performance for customers. PE Films
anticipates additional exposure to product transitions and lost business
in certain personal care materials. The estimated additional adverse
impact to future operating profit from ongoing operations relating to
such exposure is $10 million annually, which would not likely occur
until after 2017.
2015 vs. 2014
Net sales in 2015 decreased by $78.8 million versus 2014, primarily due
to lower volume from lost business and product transitions, and the
unfavorable impact from the change in the U.S. dollar value of
currencies for operations outside of the U.S.
Consistent with the pro forma information provided for fourth quarter
operating results, the table below summarizes the pro forma operating
results for 2015 and 2014 had the impact of various product transitions
and lost business and efforts to consolidate domestic PE Films
manufacturing facilities been fully realized in each period:
|
|
|
|
|
|
|
|
|
|
|
|
Twelve Months Ended December 31,
|
(In Thousands)
|
|
|
2015
|
|
|
2014
|
Operating profit from ongoing operations, as reported
|
|
|
$
|
48,275
|
|
|
$
|
60,971
|
Contribution to operating profit from ongoing operations associated
with lost business:
|
|
|
|
|
|
|
|
|
Certain babycare elastic films sold in North America
|
|
|
|
—
|
|
|
|
2,106
|
Product transitions & other lost business before restructurings &
fixed costs reduction
|
|
|
|
13,349
|
|
|
|
22,686
|
Operating profit from ongoing operations net of the impact of
business that will be fully eliminated in future periods
|
|
|
|
34,926
|
|
|
|
36,179
|
Estimated future benefit of North American facility consolidation
|
|
|
|
5,200
|
|
|
|
5,200
|
Pro forma estimated operating profit from ongoing operations
|
|
|
$
|
40,126
|
|
|
$
|
41,379
|
|
|
|
|
|
|
|
|
|
Net sales associated with lost business and product transitions that
have yet to be fully eliminated were approximately $38.5 million and
$84.5 million in 2015 and 2014, respectively.
Net of the impact of product transitions and lost business, pro forma
estimated operating profit from ongoing operations in 2015 decreased by
$1.3 million versus 2014 due to the following:
-
An increase in volume of over 6% and a favorable mix for surface
protection films ($4.2 million)
-
A decrease in volume for polyethylene overwrap films and other
personal care materials ($2.4 million);
-
The favorable lag in the pass-through of average resin costs of $1.3
million in 2015 versus a negative $0.1 million in 2014;
-
An increase in foreign currency translation and transaction losses
($3.7 million); and
-
Other factors including higher research and development costs
partially offset by lower depreciation.
Capital Expenditures and Depreciation &
Amortization
Capital expenditures in PE Films were $21.2 million in 2015 compared to
$17.0 million in 2014. Capital expenditures are projected to be $30
million in 2016, including approximately $10 million for routine items
required to support operations. Capital spending for strategic projects
in 2016 includes expansion of elastics capacity in Europe, expansion of
surface protection films capacity in China and the North American
facility consolidation. Depreciation expense was $15.4 million in 2015
and $21.1 million in 2014. Depreciation expense is projected to be $15
million in 2016. Amortization expense was $0.1 million in 2015 and $0.3
million in 2014, and is projected to be $0.1 million in 2016.
Flexible Packaging Films
A summary of fourth-quarter and full year operating results from ongoing
operations for Flexible Packaging Films (also referred to as Terphane),
which excludes the goodwill impairment charge discussed below, is
provided below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Favorable/
|
|
|
Twelve Months Ended
|
|
|
Favorable/
|
|
|
|
December 31,
|
|
|
(Unfavorable)
|
|
|
December 31,
|
|
|
(Unfavorable)
|
(In Thousands, Except Percentages)
|
|
|
2015
|
|
|
2014
|
|
|
% Change
|
|
|
2015
|
|
|
2014
|
|
|
% Change
|
Sales volume (lbs)
|
|
|
|
22,379
|
|
|
|
21,030
|
|
|
|
6.4
|
%
|
|
|
|
82,347
|
|
|
|
72,064
|
|
|
|
14.3
|
%
|
Net sales
|
|
|
$
|
27,993
|
|
|
$
|
30,965
|
|
|
|
(9.6
|
)%
|
|
|
$
|
105,332
|
|
|
$
|
114,348
|
|
|
|
(7.9
|
)%
|
Operating profit (loss) from ongoing operations
|
|
|
$
|
3,660
|
|
|
$
|
(634
|
)
|
|
|
-
|
|
|
|
$
|
5,453
|
|
|
$
|
(2,917
|
)
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth-Quarter Results vs. Prior Year Fourth
Quarter
Net sales in the fourth quarter of 2015 decreased 9.6% versus the fourth
quarter of 2014 primarily due to competitive pricing pressures and the
pass-through of lower raw material costs, partially offset by a 6.4%
increase in sales volume. Higher sales volume had a favorable impact of
approximately $2.0 million.
Operating profit (loss) from ongoing operations increased by $4.3
million in the fourth quarter of 2015 versus 2014 due to the following:
-
An improvement of $3.7 million in the fourth quarter of 2015 due to
higher volume and operating efficiencies, lower depreciation and
amortization expenses, partially offset by lower margins from
competitive pricing pressures;
-
Foreign currency transaction losses associated with U.S. dollar
denominated export sales in Brazil of $0.1 million in the fourth
quarter of 2015 versus transaction gains of $0.7 million in 2014;
-
The estimated lag in the pass through of lower raw material costs of
$0.8 million in the fourth quarter of 2015 (none in 2014);
-
Duties applied to films imported into the U.S. were zero in the fourth
quarter of 2015 as a result of the reinstatement by the U.S. in the
third quarter of 2015 of the Generalized System of Preferences (GSP)
program allowing for duty-free shipment of Terphane’s products to the
U.S., versus duties paid of $0.3 million in 2014; and
-
The favorable settlement of certain loss contingencies of $0.6 million
in the fourth quarter of 2015 versus $0.3 million in 2014.
The Company expects that Terphane will have a difficult time maintaining
the level of operating profits from ongoing operations generated in the
fourth quarter of 2015 due to continuing poor economic conditions in
Brazil, its primary market, and continuing competitive pressures.
2015 vs. 2014
Net sales in 2015 decreased 7.9% versus 2014 primarily due to
competitive pricing pressures and the pass-through to customers of lower
raw material costs, partially offset by a 14.3% increase in sales volume.
Operating profit (loss) from ongoing operations improved by $8.4 million
in 2015 versus 2014, primarily due to the following:
-
An improvement of $1.4 million in 2015 versus 2014 due to higher sales
volume and operating efficiencies, partially offset by lower margins
from competitive pricing pressures;
-
Foreign currency transaction gains associated with U.S. dollar
denominated export sales in Brazil of $3.5 million versus $0.5 million
in 2014;
-
The estimated lag in the pass through of lower raw material costs of
$1.0 million in 2015 (none in 2014);
-
Net refunds of $1.6 million in 2015 as a result of the reinstatement
of the GSP program versus duties paid of $1.1 million in 2014; and
-
The favorable settlement of certain loss contingencies of $0.6 million
in 2015 versus $0.3 million in 2014.
Capital Expenditures, Depreciation &
Amortization and Third Quarter Goodwill Impairment Charge
Capital expenditures were $3.5 million in 2015 compared to $21.8 million
in 2014. Capital expenditures in 2014 included approximately $17 million
for the capacity expansion project at a manufacturing facility in Cabo
de Santo Agostinho, Brazil. Capital expenditures are projected to be $5
million in 2016, including approximately $3 million for routine items
required to support operations. Depreciation expense was $6.8 million in
2015 and $5.8 million in 2014. Depreciation expense is projected to be
$6 million in 2016. Amortization expense was $2.9 million in 2015 and
$3.5 million in 2014, and is projected to be $3 million in 2016.
During the third quarter of 2015, the Company performed a goodwill
impairment assessment related to Terphane. This review was undertaken as
a result of the continued competitive pressures related to ongoing
unfavorable economic conditions in Terphane’s primary market of Brazil,
and excess global industry capacity. The assessment resulted in a full
write-off of the goodwill of $44.5 million associated with the
acquisition of Terphane. The Company believes that unfavorable business
conditions in its markets have shifted the competitive environment from
a regional to a global landscape and have driven price convergence and
lower product margins. Authorities in Brazil have initiated new
investigations of dumping against Peru and Bahrain. These new
investigations follow recent favorable anti-dumping rulings issued by
the Brazilian government against China, Egypt and India, which were in
addition to previous actions taken against United Arab Emirates, Mexico,
and Turkey.
Aluminum Extrusions
A summary of fourth-quarter and full year operating results from ongoing
operations for Aluminum Extrusions (also referred to as Bonnell
Aluminum) is provided below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Favorable/
|
|
|
Year Ended
|
|
|
Favorable/
|
|
|
|
December 31,
|
|
|
(Unfavorable)
|
|
|
December 31,
|
|
|
(Unfavorable)
|
(In Thousands, Except Percentages)
|
|
|
2015
|
|
|
2014
|
|
|
% Change
|
|
|
2015
|
|
|
2014
|
|
|
% Change
|
Sales volume (lbs)
|
|
|
|
42,861
|
|
|
|
39,492
|
|
|
8.5
|
%
|
|
|
|
170,045
|
|
|
|
153,843
|
|
|
10.5
|
%
|
Net sales
|
|
|
$
|
88,797
|
|
|
$
|
90,910
|
|
|
(2.3
|
)%
|
|
|
$
|
375,457
|
|
|
$
|
344,346
|
|
|
9.0
|
%
|
Operating profit from ongoing operations
|
|
|
$
|
9,569
|
|
|
$
|
7,101
|
|
|
34.8
|
%
|
|
|
$
|
30,432
|
|
|
$
|
25,664
|
|
|
18.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth-Quarter Results vs. Prior Year Fourth
Quarter
Net sales in the fourth quarter of 2015 decreased in comparison to the
fourth quarter of 2014 primarily due to a decrease in average selling
prices, which largely resulted from significantly lower aluminum costs
and mix changes. Higher sales volume had a favorable impact of
approximately $9.0 million in the fourth quarter of 2015 versus last
year. The decrease in average selling prices reduced net sales by
approximately $11.1 million. Increased demand during 2015, primarily
from the nonresidential building and construction sector, has pushed
Bonnell Aluminum’s average capacity utilization in excess of 90%.
Operating profit from ongoing operations increased in the fourth quarter
of 2015 versus 2014 primarily due to higher volume. Results also
benefited from improved efficiencies and lower utility costs.
2015 vs. 2014
Net sales in 2015 increased in comparison to 2014 primarily due to
higher sales volume in all major markets, offset by a decrease in
average selling prices. Higher sales volume had a favorable impact of
approximately $40.6 million in 2015 compared to 2014. The decrease in
average selling prices, which reduced net sales by approximately $9.5
million, were mainly due to lower aluminum costs and mix changes.
Operating profit from ongoing operations in 2015 increased $4.8 million
primarily as a result of higher volume partially offset by new hire
costs and other production inefficiencies that occurred in the first
three quarters of 2015.
Capital Expenditures and Depreciation &
Amortization
Capital expenditures for Bonnell Aluminum were $8.1 million in 2015
compared to $6.1 million in 2014. Capital expenditures are projected to
be $24 million in 2016, which includes approximately $5 million for
routine items required to support operations and approximately $14
million of a total $18 million expected to add extrusions capacity at
the Niles facility. Depreciation expense was $8.7 million in 2015
compared to $8.3 million in 2014, and is projected to be $9 million in
2016. Amortization expense was $1.0 million in 2015 and $1.6 million in
2014, and is projected to be $1 million in 2016.
Corporate Expenses, Investments, Interest and Taxes
Pension expense was $12.3 million in 2015, an unfavorable change of $5.6
million from 2014, primarily due to a drop in the discount rate. Most of
the impact on earnings from higher pension expense is reflected in
“Corporate expenses, net” in the Net Sales and Operating Profit by
Segment table. Pension expense is projected to be $11.3 million in 2016.
Corporate expenses, net increased in 2015 versus 2014 primarily due to
the increase in pension expense noted above, business development costs
and corporate severance charges. In 2015, corporate expenses, net
included non-recurring costs of $4.9 million, which consisted mainly of
business development costs of $1.0 million and severance and other
employee-related charges of $3.9 million associated with the
resignations of the Company’s former chief executive and chief financial
officers in the second quarter of 2015. In 2014, corporate expenses, net
included non-recurring costs of $0.9 million.
The Company has an investment in kaleo, Inc. (“kaléo”), a privately-held
pharmaceutical company. In 2009, kaléo licensed exclusive rights to
sanofi-aventis U.S. LLC (“Sanofi”) to commercialize an epinephrine
auto-injector in the U.S. and Canada. Sanofi began manufacturing and
distributing the epinephrine auto-injector, under the names Auvi-Q® in
the U.S. and Allerject® in Canada, in 2013. On October 28, 2015, Sanofi
announced a voluntary recall of all Auvi-Q and Allerject epinephrine
injectors that were currently on the market. The Company recognized an
unrealized loss on its investment in kaléo of $20.5 million ($15.7
million after taxes) in the fourth quarter of 2015 that was primarily
related to the adverse impact of this product recall.
Interest expense was $3.5 million in 2015 in comparison to $2.7 million
in 2014.
The effective tax rate from continuing operations was significantly
impacted by the tax effects of the special items included in the
introductory earnings reconciliation table. The comparable effective tax
rate excluding the impact of these special items was 36.2% in 2015 and
35.1% in 2014. More information on the significant differences between
the effective tax rate for income from continuing operations and the
U.S. federal statutory rate for 2015 and 2014 will be provided in the
Company’s Annual Report on Form 10-K for the year ended December 31,
2015.
CAPITAL STRUCTURE
Net debt (debt in excess of cash and cash equivalents) was $59.8 million
at December 31, 2015, compared with $87.2 million at December 31, 2014.
Net debt is a financial measure that is not calculated or presented in
accordance with United States generally accepted accounting principles
(“GAAP”). See the Notes to the Financial Tables for a reconciliation of
this non-GAAP financial measure to the most directly comparable GAAP
financial measure.
FORWARD-LOOKING AND CAUTIONARY STATEMENTS
Some of the information contained in this press release may constitute
“forward-looking statements” within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995. When
we use the words “believe,” “estimate,” “anticipate,” “expect,”
“project,” “likely,” “may” and similar expressions, we do so to identify
forward-looking statements. Such statements are based on our then
current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from
those addressed in the forward-looking statements. It is possible that
our actual results and financial condition may differ, possibly
materially, from the anticipated results and financial condition
indicated in or implied by these forward-looking statements.
Accordingly, you should not place undue reliance on these
forward-looking statements. Factors that could cause actual results to
differ from expectations include, without limitation: acquired
businesses, including Terphane Holdings LLC (“Terphane”) and AACOA, Inc.
(“AACOA”), may not achieve expected levels of revenue, profit,
productivity, or otherwise perform as expected; acquisitions, including
the acquisitions of Terphane and AACOA, involve special risks, including
without limitation, diversion of management’s time and attention from
our existing businesses, the potential assumption of unanticipated
liabilities and contingencies and potential difficulties in integrating
acquired businesses and achieving anticipated operational improvements;
PE Films is highly dependent on sales associated with one customer — The
Procter & Gamble Company (P&G”) and PE Films may not be able to mitigate
the impact of the expected decline in net sales to P&G on operating
profit from ongoing operations; growth of PE Films depends on its
ability to develop and deliver new products at competitive prices; sales
volume and profitability of Aluminum Extrusions are cyclical and highly
dependent on economic conditions of end-use markets in the U.S.,
particularly in the building and construction sector, and can also be
subject to seasonal slowdowns; Aluminum Extrusions’ efforts to expand
product offerings and broaden its customer base may not be successful;
substantial international operations subject Tredegar to risks of doing
business in countries outside the U.S., which could adversely affect its
business, financial condition and results of operations; future
performance is influenced by costs incurred by our operating companies,
including, for example, the cost of energy and raw materials; and the
other factors discussed in the reports Tredegar files with or furnishes
to the SEC from time to time, including the risks and important factors
set forth in additional detail in “Risk Factors” in Part I, Item 1A of
Tredegar’s 2015 Annual Report on Form 10-K (the “2015 Form 10-K”) to be
filed with the SEC. Readers are urged to review and consider carefully
the disclosures Tredegar makes in its filings with the SEC, including
the 2015 Form 10-K when it is filed, except as required by applicable
law.
Tredegar does not undertake, and expressly disclaims any duty, to update
any forward-looking statement made in this press release to reflect any
change in management’s expectations or any change in conditions,
assumptions or circumstances on which such statements are based.
To the extent that the financial information portion of this press
release contains non-GAAP financial measures, it also presents both the
most directly comparable financial measures calculated and presented in
accordance with GAAP and a quantitative reconciliation of the difference
between any such non-GAAP measures and such comparable GAAP financial
measures. Accompanying the reconciliation is management’s statement
concerning the reasons why management believes that presentation of
non-GAAP measures provides useful information to investors concerning
Tredegar’s financial condition and results of operations.
Reconciliations of non-GAAP financial measures are provided in the Notes
to the Financial Tables included with this press release and can also be
found within “Presentations” in the “Investors” section of our website, www.tredegar.com.
Tredegar uses its website as a channel of distribution of material
company information. Financial information and other material
information regarding Tredegar is posted on and assembled in the
“Investors” section of our website.
Tredegar Corporation is a manufacturer of plastic films and aluminum
extrusions. A global company headquartered in Richmond, Virginia,
Tredegar had 2015 sales of $896 million. With approximately 2,800
employees, the company operates manufacturing facilities in North
America, South America, Europe, and Asia.
|
Tredegar Corporation
|
Condensed Consolidated Statements of Income
|
(In Thousands, Except Per-Share Data)
|
(Unaudited)
|
|
|
|
|
Three Months Ended
|
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2015
|
|
|
2014
|
|
|
2015
|
|
|
2014
|
Sales
|
|
|
$
|
216,989
|
|
|
|
$
|
239,219
|
|
|
|
$
|
896,177
|
|
|
|
$
|
951,826
|
|
Other income (expense), net (a) (d) (e) (f)
|
|
|
|
(20,492
|
)
|
|
|
|
(379
|
)
|
|
|
|
(20,113
|
)
|
|
|
|
(6,697
|
)
|
|
|
|
|
196,497
|
|
|
|
|
238,840
|
|
|
|
|
876,064
|
|
|
|
|
945,129
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold (a)
|
|
|
|
169,832
|
|
|
|
|
197,214
|
|
|
|
|
725,459
|
|
|
|
|
778,113
|
|
Freight
|
|
|
|
6,908
|
|
|
|
|
7,896
|
|
|
|
|
29,838
|
|
|
|
|
28,793
|
|
Selling, R&D and general expenses (a)
|
|
|
|
22,478
|
|
|
|
|
20,937
|
|
|
|
|
88,084
|
|
|
|
|
81,673
|
|
Amortization of intangibles
|
|
|
|
960
|
|
|
|
|
1,158
|
|
|
|
|
4,073
|
|
|
|
|
5,395
|
|
Interest expense
|
|
|
|
823
|
|
|
|
|
962
|
|
|
|
|
3,502
|
|
|
|
|
2,713
|
|
Asset impairments and costs associated with exit and disposal
activities (a)
|
|
|
|
1,508
|
|
|
|
|
374
|
|
|
|
|
3,850
|
|
|
|
|
3,026
|
|
Goodwill impairment charge (b)
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
44,465
|
|
|
|
|
—
|
|
|
|
|
|
202,509
|
|
|
|
|
228,541
|
|
|
|
|
899,271
|
|
|
|
|
899,713
|
|
Income (loss) from continuing operations before income taxes
|
|
|
|
(6,012
|
)
|
|
|
|
10,299
|
|
|
|
|
(23,207
|
)
|
|
|
|
45,416
|
|
Income taxes from continuing operations (g)
|
|
|
|
(136
|
)
|
|
|
|
(2,755
|
)
|
|
|
|
8,928
|
|
|
|
|
9,387
|
|
Income (loss) from continuing operations
|
|
|
|
(5,876
|
)
|
|
|
|
13,054
|
|
|
|
|
(32,135
|
)
|
|
|
|
36,029
|
|
Income (loss) from discontinued operations, net of tax (c)
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
850
|
|
Net income (loss)
|
|
|
$
|
(5,876
|
)
|
|
|
$
|
13,054
|
|
|
|
$
|
(32,135
|
)
|
|
|
$
|
36,879
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
|
$
|
(0.18
|
)
|
|
|
$
|
0.40
|
|
|
|
$
|
(0.99
|
)
|
|
|
$
|
1.12
|
|
Discontinued operations (c)
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
0.02
|
|
Net income (loss)
|
|
|
$
|
(0.18
|
)
|
|
|
$
|
0.40
|
|
|
|
$
|
(0.99
|
)
|
|
|
$
|
1.14
|
|
Diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
|
$
|
(0.18
|
)
|
|
|
$
|
0.40
|
|
|
|
$
|
(0.99
|
)
|
|
|
$
|
1.11
|
|
Discontinued operations (c)
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
0.02
|
|
Net income (loss)
|
|
|
$
|
(0.18
|
)
|
|
|
$
|
0.40
|
|
|
|
$
|
(0.99
|
)
|
|
|
$
|
1.13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used to compute earnings (loss) per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
|
32,614
|
|
|
|
|
32,335
|
|
|
|
|
32,578
|
|
|
|
|
32,302
|
|
Diluted
|
|
|
|
32,614
|
|
|
|
|
32,449
|
|
|
|
|
32,578
|
|
|
|
|
32,554
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tredegar Corporation
|
Net Sales and Operating Profit by Segment
|
(In Thousands)
|
(Unaudited)
|
|
|
|
|
Three Months Ended
|
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2015
|
|
|
2014
|
|
|
2015
|
|
|
2014
|
Net Sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PE Films
|
|
|
$
|
93,291
|
|
|
|
$
|
109,448
|
|
|
|
$
|
385,550
|
|
|
|
$
|
464,339
|
|
Flexible Packaging Films
|
|
|
|
27,993
|
|
|
|
|
30,965
|
|
|
|
|
105,332
|
|
|
|
|
114,348
|
|
Aluminum Extrusions
|
|
|
|
88,797
|
|
|
|
|
90,910
|
|
|
|
|
375,457
|
|
|
|
|
344,346
|
|
Total net sales
|
|
|
|
210,081
|
|
|
|
|
231,323
|
|
|
|
|
866,339
|
|
|
|
|
923,033
|
|
Add back freight
|
|
|
|
6,908
|
|
|
|
|
7,896
|
|
|
|
|
29,838
|
|
|
|
|
28,793
|
|
Sales as shown in the Consolidated Statements of Income
|
|
|
$
|
216,989
|
|
|
|
$
|
239,219
|
|
|
|
$
|
896,177
|
|
|
|
$
|
951,826
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PE Films:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ongoing operations
|
|
|
$
|
12,426
|
|
|
|
$
|
13,797
|
|
|
|
$
|
48,275
|
|
|
|
$
|
60,971
|
|
Plant shutdowns, asset impairments, restructurings and other (a)
|
|
|
|
(2,129
|
)
|
|
|
|
43
|
|
|
|
|
(4,180
|
)
|
|
|
|
(12,236
|
)
|
Flexible Packaging Films:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ongoing operations
|
|
|
|
3,660
|
|
|
|
|
(634
|
)
|
|
|
|
5,453
|
|
|
|
|
(2,917
|
)
|
Plant shutdowns, asset impairments, restructurings and other (a)
|
|
|
|
—
|
|
|
|
|
(292
|
)
|
|
|
|
(185
|
)
|
|
|
|
(591
|
)
|
Goodwill impairment charge (b)
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
(44,465
|
)
|
|
|
|
—
|
|
Aluminum Extrusions:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ongoing operations
|
|
|
|
9,569
|
|
|
|
|
7,101
|
|
|
|
|
30,432
|
|
|
|
|
25,664
|
|
Plant shutdowns, asset impairments, restructurings and other (a)
|
|
|
|
(344
|
)
|
|
|
|
(676
|
)
|
|
|
|
(708
|
)
|
|
|
|
(976
|
)
|
Total
|
|
|
|
23,182
|
|
|
|
|
19,339
|
|
|
|
|
34,622
|
|
|
|
|
69,915
|
|
Interest income
|
|
|
|
47
|
|
|
|
|
169
|
|
|
|
|
294
|
|
|
|
|
588
|
|
Interest expense
|
|
|
|
823
|
|
|
|
|
962
|
|
|
|
|
3,502
|
|
|
|
|
2,713
|
|
Gain (loss) on investment accounted for under fair value method (d)
|
|
|
|
(20,500
|
)
|
|
|
|
(900
|
)
|
|
|
|
(20,500
|
)
|
|
|
|
2,000
|
|
Gain on sale of investment property (e)
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
1,208
|
|
Stock option-based compensation costs
|
|
|
|
(88
|
)
|
|
|
|
328
|
|
|
|
|
483
|
|
|
|
|
1,272
|
|
Corporate expenses, net (a) (f)
|
|
|
|
8,006
|
|
|
|
|
7,019
|
|
|
|
|
33,638
|
|
|
|
|
24,310
|
|
Income (loss) from continuing operations before income taxes
|
|
|
|
(6,012
|
)
|
|
|
|
10,299
|
|
|
|
|
(23,207
|
)
|
|
|
|
45,416
|
|
Income taxes from continuing operations (g)
|
|
|
|
(136
|
)
|
|
|
|
(2,755
|
)
|
|
|
|
8,928
|
|
|
|
|
9,387
|
|
Income (loss) from continuing operations
|
|
|
|
(5,876
|
)
|
|
|
|
13,054
|
|
|
|
|
(32,135
|
)
|
|
|
|
36,029
|
|
Income (loss) from discontinued operations, net of tax (c)
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
850
|
|
Net income (loss)
|
|
|
$
|
(5,876
|
)
|
|
|
$
|
13,054
|
|
|
|
$
|
(32,135
|
)
|
|
|
$
|
36,879
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tredegar Corporation
|
Condensed Consolidated Balance Sheets
|
(In Thousands)
|
(Unaudited)
|
|
|
|
|
December 31, 2015
|
|
|
December 31, 2014
|
Assets
|
|
|
|
|
|
|
|
|
Cash & cash equivalents
|
|
|
$
|
44,156
|
|
|
$
|
50,056
|
Accounts & other receivables, net
|
|
|
|
94,217
|
|
|
|
113,341
|
Income taxes recoverable
|
|
|
|
360
|
|
|
|
877
|
Inventories
|
|
|
|
65,325
|
|
|
|
74,308
|
Deferred income taxes
|
|
|
|
—
|
|
|
|
8,877
|
Prepaid expenses & other
|
|
|
|
6,946
|
|
|
|
8,283
|
Total current assets
|
|
|
|
211,004
|
|
|
|
255,742
|
Property, plant & equipment, net
|
|
|
|
231,315
|
|
|
|
269,957
|
Goodwill & other intangibles, net
|
|
|
|
153,072
|
|
|
|
215,129
|
Other assets
|
|
|
|
27,869
|
|
|
|
47,798
|
Total assets
|
|
|
$
|
623,260
|
|
|
$
|
788,626
|
Liabilities and Shareholders’ Equity
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
|
$
|
84,148
|
|
|
$
|
94,131
|
Accrued expenses
|
|
|
|
33,653
|
|
|
|
32,049
|
Total current liabilities
|
|
|
|
117,801
|
|
|
|
126,180
|
Long-term debt
|
|
|
|
104,000
|
|
|
|
137,250
|
Deferred income taxes
|
|
|
|
18,656
|
|
|
|
39,255
|
Other noncurrent liabilities
|
|
|
|
110,055
|
|
|
|
113,912
|
Shareholders’ equity
|
|
|
|
272,748
|
|
|
|
372,029
|
Total liabilities and shareholders’ equity
|
|
|
$
|
623,260
|
|
|
$
|
788,626
|
|
|
|
|
|
|
|
|
|
|
Tredegar Corporation
|
Condensed Consolidated Statement of Cash Flows
|
(In Thousands)
|
(Unaudited)
|
|
|
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
|
2015
|
|
|
2014
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
$
|
(32,135
|
)
|
|
|
$
|
36,879
|
|
Adjustments for noncash items:
|
|
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
|
30,909
|
|
|
|
|
35,423
|
|
Amortization of intangibles
|
|
|
|
4,073
|
|
|
|
|
5,395
|
|
Goodwill impairment charge
|
|
|
|
44,465
|
|
|
|
|
—
|
|
Deferred income taxes
|
|
|
|
(10,523
|
)
|
|
|
|
(11,489
|
)
|
Accrued pension income and post-retirement benefits
|
|
|
|
12,521
|
|
|
|
|
6,974
|
|
(Gain) loss on investment accounted for under the fair value method
|
|
|
|
20,500
|
|
|
|
|
(2,000
|
)
|
Loss on asset impairments and divestitures
|
|
|
|
403
|
|
|
|
|
993
|
|
Net gain on sale of assets
|
|
|
|
(11
|
)
|
|
|
|
(1,031
|
)
|
Changes in assets and liabilities, net of effects of acquisitions
and divestitures:
|
|
|
|
|
|
|
|
|
|
|
Accounts and other receivables
|
|
|
|
9,180
|
|
|
|
|
(18,696
|
)
|
Inventories
|
|
|
|
1,137
|
|
|
|
|
(8,803
|
)
|
Income taxes recoverable/payable
|
|
|
|
(1,849
|
)
|
|
|
|
(906
|
)
|
Prepaid expenses and other
|
|
|
|
(1,256
|
)
|
|
|
|
496
|
|
Accounts payable and accrued expenses
|
|
|
|
(2,455
|
)
|
|
|
|
5,554
|
|
Other, net
|
|
|
|
(703
|
)
|
|
|
|
2,446
|
|
Net cash provided by operating activities
|
|
|
|
74,256
|
|
|
|
|
51,235
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures
|
|
|
|
(32,831
|
)
|
|
|
|
(44,898
|
)
|
Sale of investment property
|
|
|
|
—
|
|
|
|
|
4,500
|
|
Proceeds from the sale of assets and other
|
|
|
|
1,416
|
|
|
|
|
2,125
|
|
Net cash used in investing activities
|
|
|
|
(31,415
|
)
|
|
|
|
(38,273
|
)
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
|
Borrowings
|
|
|
|
107,000
|
|
|
|
|
116,000
|
|
Debt principal payments
|
|
|
|
(140,328
|
)
|
|
|
|
(117,779
|
)
|
Dividends paid
|
|
|
|
(13,725
|
)
|
|
|
|
(11,007
|
)
|
Proceeds from exercise of stock options and other
|
|
|
|
2,858
|
|
|
|
|
410
|
|
Net cash used in financing activities
|
|
|
|
(44,195
|
)
|
|
|
|
(12,376
|
)
|
Effect of exchange rate changes on cash
|
|
|
|
(4,546
|
)
|
|
|
|
(3,147
|
)
|
Decrease in cash and cash equivalents
|
|
|
|
(5,900
|
)
|
|
|
|
(2,561
|
)
|
Cash and cash equivalents at beginning of period
|
|
|
|
50,056
|
|
|
|
|
52,617
|
|
Cash and cash equivalents at end of period
|
|
|
$
|
44,156
|
|
|
|
$
|
50,056
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes to the Financial Tables
|
(Unaudited)
|
|
(a)
|
|
Plant shutdowns, asset impairments, restructurings and other in the
fourth quarter of 2015 include:
|
|
|
|
-
Pretax charge of $1.1 million ($0.4 million included in “Selling, R&D
and general expense” in the condensed consolidated statement of
income) for severance and other employee-related costs associated with
restructurings in PE Films;
-
Pretax charges of $1.0 million associated with the consolidation of
domestic PE films manufacturing facilities, which includes severance
and other employee-related costs of $0.4 million, accelerated
depreciation of $0.1 million (included in “Cost of goods sold” in the
condensed consolidated statements of income), asset impairments of
$84,000 and other facility consolidation-related expenses of $0.4
million ($89,000 is included in “Cost of goods sold” in the condensed
consolidated statements of income);
-
Pretax charges of $1.0 million associated with a non-recurring
business development project (included in “Selling, R&D and general
expense” in the condensed consolidated statement of income and
“Corporate expenses, net” in the statement of net sales and operating
profit by segment);
-
Pretax charges of $0.3 million related to expected future
environmental costs at the Company’s aluminum extrusions manufacturing
facility in Newnan, Georgia (included in “Cost of goods sold” in the
condensed consolidated statements of income); and
-
Pretax charges of $31,000 associated with the shutdown of the aluminum
extrusions manufacturing facility in Kentland, Indiana.
Plant shutdowns, asset impairments, restructurings and other charges in
2015 include:
-
Pretax charges of $3.9 million (included in “Selling, R&D and general
expense” in the condensed consolidated statements of income and
“Corporate expenses, net” in the statement of net sales and operating
profit by segment) for severance and other employee-related costs
associated with the resignation of the Company’s former chief
executive and chief financial officers;
-
Pretax charges of $2.2 million associated with the consolidation of
domestic PE films manufacturing facilities, which includes severance
and other employee-related costs of $0.8 million, asset impairments of
$0.4 million, accelerated depreciation of $0.4 million (included in
“Cost of goods sold” in the condensed consolidated statements of
income) and other facility consolidation-related expenses of $0.6
million ($0.1 million is included in “Cost of goods sold” in the
condensed consolidated statements of income);
-
Pretax charge of $2.2 million for severance and other employee-related
costs ($0.4 million included in “Selling, R&D and general expense” in
the condensed consolidated statement of income) associated with
restructurings in PE Films ($2.0 million), Flexible Packaging Films
($0.2 million), Aluminum Extrusions ($35,000) and Corporate ($26,000
included in “Corporate expenses, net” in the statement of net sales
and operating profit by segment);
-
Pretax charges of $1.0 million associated with a non-recurring
business development project (included in “Selling, R&D and general
expense” in the condensed consolidated statement of income and
“Corporate expenses, net” in the statement of net sales and operating
profit by segment);
-
Pretax charges of $0.4 million associated with the shutdown of the
aluminum extrusions manufacturing facility in Kentland, Indiana; and
-
Pretax charges of $0.3 million related to expected future
environmental costs at the Company’s aluminum extrusions manufacturing
facility in Newnan, Georgia (included in “Cost of goods sold” in the
condensed consolidated statements of income).
Plant shutdowns, asset impairments, restructurings and other charges in
the fourth quarter of 2014 include:
-
Pretax charges of $0.7 million related to expected future
environmental costs at the Company’s aluminum extrusions manufacturing
facility in Newnan, Georgia (included in “Cost of goods sold” in the
condensed consolidated statements of income);
-
Pretax charges of $0.5 million associated with severance and other
employee-related costs associated with restructurings in PE Films
($0.2 million) and Flexible Packaging Films ($0.3 million);
-
Pretax gain of $0.1 million related to the sale of a previously
shutdown PE film products manufacturing facility in LaGrange, Georgia
(included in “Other income (expense), net” in the condensed
consolidated statements of income);
-
Pretax adjustment of $0.1 million to income to reverse previously
accrued severance and other employee-related costs associated with the
shutdown of the PE film products manufacturing facility in Red
Springs, North Carolina; and
-
Pretax charges of $11,000 associated with the shutdown of the aluminum
extrusions manufacturing facility in Kentland, Indiana.
Plant shutdowns, asset impairments, restructurings and other items in
2014 include:
-
Pretax charge of $10.0 million (included in “Other income (expense),
net” in the condensed consolidated statements of income) associated
with a one-time, lump sum license payment to 3M after the Company
settled all litigation issues associated with a patent infringement
complaint;
-
Pretax charges of $2.3 million associated with severance and other
employee-related costs associated with restructurings in PE Films
($1.7 million), Flexible Packaging Films ($0.6 million) and Aluminum
Extrusions ($31,000);
-
Pretax charges of $0.9 million related to expected future
environmental costs at the Company’s aluminum extrusions manufacturing
facility in Newnan, Georgia (included in “Cost of goods sold” in the
condensed consolidated statements of income);
-
Pretax charges of $0.7 million associated with the shutdown of the PE
film products manufacturing facility in Red Springs, North Carolina,
which includes severance and other employee-related costs of $0.4
million and asset impairment and other shutdown-related charges of
$0.3 million;
-
Pretax gain of $0.1 million related to the sale of a previously
shutdown PE film products manufacturing facility in LaGrange, Georgia
(included in “Other income (expense), net” in the condensed
consolidated statements of income); and
-
Pretax charges of $54,000 associated with the shutdown of the aluminum
extrusions manufacturing facility in Kentland, Indiana.
|
|
|
(b)
|
|
Goodwill impairment charge of $44.5 million ($44.5 million after
taxes) recognized in Flexible Packaging Films in the third quarter
of 2015 upon completion of an impairment analysis performed as of
September 30, 2015. This non-operating, non-cash charge, as computed
under U.S. GAAP, resulted from continuing competitive pressures
primarily related to ongoing unfavorable economic conditions in its
primary market of Brazil and excess global capacity in the industry.
|
|
|
|
(c)
|
|
On February 12, 2008, Tredegar sold its aluminum extrusions business
in Canada for a purchase price of approximately $25 million. All
historical results for this business were previously reported in
discontinued operations. Accruals for indemnifications under the
purchase agreement related to environmental matters were adjusted in
2014, resulting in income from discontinued operations of $0.9
million ($0.9 million after tax).
|
|
|
|
(d)
|
|
The unrealized gain (loss) on the Company’s investment in kaleo,
Inc. (“kaléo”) was a loss of $20.5 million in the fourth quarter of
2015 and for the full year 2015. In 2009, kaléo licensed exclusive
rights to sanofi-aventis U.S. LLC (“Sanofi”) to commercialize an
epinephrine auto-injector in the U.S. and Canada. Sanofi began
manufacturing and distributing the epinephrine auto-injector, under
the names Auvi-Q® in the U.S. and Allerject® in Canada, in 2013.
Sanofi announced on October 28, 2015 a voluntary recall of all
Auvi-Q and Allerject epinephrine injectors currently on the market.
The unrealized loss in the fourth quarter of and full year 2015
reflects the estimated adverse impact of this product recall.
|
|
|
|
|
|
The unrealized gain (loss) on the Company’s investment in kaléo was
a loss of $0.9 million in the fourth quarter of 2014 and a net gain
of $2.0 million for the full year 2014. The unrealized loss in the
fourth quarter of 2014 was primarily attributed to unfavorable
adjustments in the fair value due to a reassessment of the amount
and timing of sales associated with one of kaléo’s commercialized
products. The net unrealized gain in 2014 can be primarily related
to favorable adjustments for the passage of time as cash flows
associated with achieving product development and commercialization
milestones are discounted at 45% for their high degree of risk and
the impact of reducing the weighted average cost of capital used to
discount cash flow projections after kaléo commercialized a second
product, partially offset by unfavorable adjustments in the fair
value due to a reassessment of the amount and timing of estimated
cash flows associated with kaléo’s commercialized products.
|
|
|
|
(e)
|
|
A pretax gain of $1.2 million (included in “Other income (expense),
net” in the condensed consolidated statement of income) was realized
on the sale of a portion of its investment property in Alleghany and
Bath Counties, Virginia in the second quarter of 2014.
|
|
|
|
(f)
|
|
Pretax charges of $0.8 million in 2014 (none in the fourth quarter
of 2015 and 2014 and full year 2015) related to unrealized losses
for the Company’s investment in the Harbinger Capital Partners
Special Situations Fund, L.P. were recorded as a result of a
reduction in the value of the Company’s investment that is not
expected to be temporary. The impairment charge is included in
“Other income (expense), net” in the condensed consolidated
statements of income and in “Corporate expenses, net” in the
statement of net sales and operating profit by segment.
|
|
|
|
(g)
|
|
Income taxes from continuing operations in 2015 and 2014 included
the net reduction of a valuation allowance, associated with
expected limitations on the utilization of capital losses, of $0.5
million and $4.9 million, respectively, due to the Company’s
change in judgment related to the realization of the related
deferred tax asset. These capital loss carryforwards were
previously offset by a valuation allowance associated with
expected limitations on the utilization of these assumed capital
losses. Income taxes from continuing operations in 2015 and 2014
also included adjustments of $0.9 million and $2.2 million,
respectively, to reverse previously accrued deferred tax
liabilities arising from changes in tax basis due to foreign
currency translation adjustments and unremitted earnings.
|
|
|
|
(h)
|
|
Net debt is calculated as follows:
|
|
|
|
|
|
|
|
|
|
|
(in millions)
|
|
|
December 31, 2015
|
|
|
December 31, 2014
|
Debt
|
|
|
$
|
104.0
|
|
|
$
|
137.3
|
Less: Cash and cash equivalents
|
|
|
|
44.2
|
|
|
|
50.1
|
Net debt
|
|
|
$
|
59.8
|
|
|
$
|
87.2
|
|
|
|
|
|
|
|
|
|
Net debt is not intended to represent total debt as defined by GAAP.
Net debt is utilized by management in evaluating the Company’s
financial leverage and equity valuation, and management believes
that investors also may find net debt to be helpful for the same
purposes.
|
|
|
|
(i)
|
|
The pre-tax and after-tax effects of gains (losses) associated with
plant shutdowns, asset impairments and restructurings, gains
(losses) from the sale of assets and other (which includes
unrealized gains and losses for an investment accounted for under
the fair value method) and goodwill impairment charge have been
presented separately and removed from income (loss) from continuing
operations as reported under U.S. GAAP to determine Tredegar’s
presentation of net income from ongoing operations. Net income from
ongoing operations is a key financial and analytical measure used by
Tredegar to gauge the operating performance of its ongoing
operations. It is not intended to represent the stand-alone results
for Tredegar’s ongoing operations under U.S. GAAP and should not be
considered as an alternative to net income from continuing
operations as defined by U.S. GAAP. It excludes items that we
believe do not relate to Tredegar’s ongoing operations. A
reconciliation of the pre-tax and post-tax balances attributed to
net income from ongoing operations for the years ended December 31,
2015 and 2014 are shown below in order to show its impact upon the
effective tax rate:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in millions)
|
|
|
Pre-Tax
|
|
|
Taxes Expense
(Benefit)
|
|
|
After-Tax
|
|
|
Effective
Tax Rate
|
Year Ended December 31, 2015
|
|
|
(a)
|
|
|
(b)
|
|
|
|
|
|
(b)/(a)
|
Net income (loss) from continuing operations as reported under U.S.
GAAP
|
|
|
$
|
(23.2
|
)
|
|
|
$
|
8.9
|
|
|
$
|
(32.1
|
)
|
|
|
(38.5
|
)%
|
(Gains) losses associated with plant shutdowns, asset impairments
and restructurings
|
|
|
|
4.8
|
|
|
|
|
1.8
|
|
|
|
3.0
|
|
|
|
|
|
(Gains) losses from sale of assets and other
|
|
|
|
25.8
|
|
|
|
|
8.1
|
|
|
|
17.7
|
|
|
|
|
|
Goodwill impairment charge
|
|
|
|
44.5
|
|
|
|
|
—
|
|
|
|
44.5
|
|
|
|
|
|
Net income from ongoing operations
|
|
|
$
|
51.9
|
|
|
|
$
|
18.8
|
|
|
$
|
33.1
|
|
|
|
36.2
|
%
|
Year Ended December 31, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) from continuing operations as reported under U.S.
GAAP
|
|
|
$
|
45.4
|
|
|
|
$
|
9.4
|
|
|
$
|
36.0
|
|
|
|
20.7
|
%
|
(Gains) losses associated with plant shutdowns, asset impairments
and restructurings
|
|
|
|
3.0
|
|
|
|
|
1.0
|
|
|
|
2.0
|
|
|
|
|
|
(Gains) losses from sale of assets and other(1)
|
|
|
|
8.3
|
|
|
|
|
9.5
|
|
|
|
(1.2
|
)
|
|
|
|
|
Net income from ongoing operations
|
|
|
$
|
56.7
|
|
|
|
$
|
19.9
|
|
|
$
|
36.8
|
|
|
|
35.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) See note (f) for discussion of certain tax
adjustments in 2014.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
View source version on businesswire.com: http://www.businesswire.com/news/home/20160229005976/en/
Copyright Business Wire 2016